<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01448291</url>
  </required_header>
  <id_info>
    <org_study_id>CRC-NVR11</org_study_id>
    <secondary_id>11-01-FB-0003</secondary_id>
    <nct_id>NCT01448291</nct_id>
  </id_info>
  <brief_title>Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers</brief_title>
  <official_title>The Effects of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) on Vaginal Innate and Inflammatory Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Virginia Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Virginia Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is not known if the use of NuvaRing® alters these innate and inflammatory biomarkers of&#xD;
      inflammation.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      The hypothesis is that NuvaRing® will alter inflammatory biomarkers of inflammation, such as&#xD;
      vaginal defensin and cytokine levels, resulting in an overall anti-inflammatory milieu in the&#xD;
      vagina.&#xD;
&#xD;
      Specific aims of this study are to:&#xD;
&#xD;
        1. Determine biomarkers of inflammation, including defensins and cytokines, concentrations&#xD;
           in women with normal vaginal flora (Nugent Score 0 - 3) before and after NuvaRing® use&#xD;
&#xD;
        2. Determine changes in the integrity of cervicovaginal epithelium and leukocytic&#xD;
           concentration before and after treatment with NuvaRing®&#xD;
&#xD;
        3. Monitor for changes in the Nugent score before and after NuvaRing® use&#xD;
&#xD;
        4. Assess the antimicrobial activity of vaginal fluid before and after NuvaRing® use&#xD;
&#xD;
        5. Assess HIV infectivity ex vivo on biopsy specimens before and after NuvaRing® use&#xD;
&#xD;
      Methods This is a prospective, open-label, nonrandomized study. Participants will serve as&#xD;
      their own controls. The Clinical Research Center of Eastern Virginia Medical School, Norfolk,&#xD;
      Virginia, U.S.A. will be the only study site.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To complete specific aim #1, the investigators will use commercially available elisa&#xD;
           kits to measure human defensins, inflammatory cytokines, and anti-inflammatory cytokines&#xD;
           in vaginal fluid washings collected before and after use of NuvaRing.&#xD;
&#xD;
        2. To complete specific aim #2, the investigators will collect biopsies of the uterine&#xD;
           cervix before and after NuvaRing use. Specimens will undergo histopathological measures&#xD;
           for overall appearance, epithelial integrity, epithelial thickness, leukocyte&#xD;
           infiltration, congestion, and edema. The investigators will quantitate the number of&#xD;
           CD45+ and NFkB+ cells using immunohistology in the cervical epithelium.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine biomarkers of inflammation, including defensins and cytokines, concentrations in women with normal vaginal flora (Nugent Score 0 - 3) after 3 months of NuvaRing® use</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine changes in the integrity of cervicovaginal epithelium and leukocytic concentration after 3 months of treatment with NuvaRing®</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Vaginosis, Bacterial</condition>
  <arm_group>
    <arm_group_label>Nuvaring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single-group study in which data points after use of the etonogestrel/ethinyl estradiol vaginal ring will be compared to baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring</intervention_name>
    <description>Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) for 3 months</description>
    <arm_group_label>Nuvaring</arm_group_label>
    <other_name>NuvaRing®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women (age 18 - 45) interested in using NuvaRing® for contraception for 3 or more&#xD;
             months, and women who are not at risk for pregnancy (i.e. abstinent, tubal&#xD;
             sterilization, partner with vasectomy)&#xD;
&#xD;
          2. Women with a normal menstrual cycle (21-35 days) for the past three cycles&#xD;
&#xD;
          3. Women with normal pelvic anatomy (by physical exam)&#xD;
&#xD;
          4. Negative urine pregnancy test&#xD;
&#xD;
          5. Normal pap smear within the past 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. Current breastfeeding&#xD;
&#xD;
          3. Less than 6 weeks post partum&#xD;
&#xD;
          4. Current IUD or Implanon use&#xD;
&#xD;
          5. Depot Medroxyprogesterone Acetate use within the past 6 months&#xD;
&#xD;
          6. Current diagnosis of uterine infection&#xD;
&#xD;
          7. Use of hormonal contraception within the past 30 days&#xD;
&#xD;
          8. Current cervical dysplasia&#xD;
&#xD;
          9. Chronic immune suppression&#xD;
&#xD;
         10. Chronic use of immune suppressors such as steroids&#xD;
&#xD;
         11. Chronic antibiotic use&#xD;
&#xD;
         12. Diabetes or fasting blood glucose &gt;105&#xD;
&#xD;
         13. Hysterectomy&#xD;
&#xD;
         14. Uncontrolled hypertension (systolic BP≥140/ diastolic BP≥ 90)&#xD;
&#xD;
         15. Migraine headaches complicated by aura or focal neurologic deficits&#xD;
&#xD;
         16. Menopause&#xD;
&#xD;
         17. Standard contraindications to combined oral contraceptive use (thrombophilia, active&#xD;
             liver disease, active deep venous thrombosis, history of thrombosis)&#xD;
&#xD;
         18. Use of tobacco products ≥ 35 years of age&#xD;
&#xD;
         19. Two or more symptomatic genital herpes simplex virus (HSV) outbreaks in past 12 months&#xD;
&#xD;
         20. Human immunodeficiency virus&#xD;
&#xD;
         21. Vulvovaginal candidiasis&#xD;
&#xD;
         22. Trichamonas vaginalis&#xD;
&#xD;
         23. Neisseria gonorrhea&#xD;
&#xD;
         24. Chlamydia trachomatis&#xD;
&#xD;
         25. Bacterial vaginosis&#xD;
&#xD;
         26. Nugent scores of 4 or greater&#xD;
&#xD;
         27. Use of any other study medication within the past 30 days&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas D Kimble, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Virginia Medical School/CONRAD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia Caul</last_name>
    <phone>7574465808</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Center at Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Caul</last_name>
      <phone>757-446-5808</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Iqbal SM, Kaul R. Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol. 2008 Jan;59(1):44-54. Review.</citation>
    <PMID>18154595</PMID>
  </reference>
  <reference>
    <citation>Valore EV, Park CH, Igreti SL, Ganz T. Antimicrobial components of vaginal fluid. Am J Obstet Gynecol. 2002 Sep;187(3):561-8.</citation>
    <PMID>12237628</PMID>
  </reference>
  <reference>
    <citation>Fan SR, Liu XP, Liao QP. Human defensins and cytokines in vaginal lavage fluid of women with bacterial vaginosis. Int J Gynaecol Obstet. 2008 Oct;103(1):50-4. doi: 10.1016/j.ijgo.2008.05.020. Epub 2008 Jul 16.</citation>
    <PMID>18635180</PMID>
  </reference>
  <reference>
    <citation>John M, Keller MJ, Fam EH, Cheshenko N, Hogarty K, Kasowitz A, Wallenstein S, Carlucci MJ, Tuyama AC, Lu W, Klotman ME, Lehrer RI, Herold BC. Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis. 2005 Nov 15;192(10):1731-40. Epub 2005 Oct 13.</citation>
    <PMID>16235171</PMID>
  </reference>
  <reference>
    <citation>Cherpes TL, Marrazzo JM, Cosentino LA, Meyn LA, Murray PJ, Hillier SL. Hormonal contraceptive use modulates the local inflammatory response to bacterial vaginosis. Sex Transm Infect. 2008 Feb;84(1):57-61. Epub 2007 Oct 2.</citation>
    <PMID>17911138</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>July 8, 2011</study_first_submitted>
  <study_first_submitted_qc>October 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2011</study_first_posted>
  <last_update_submitted>April 23, 2012</last_update_submitted>
  <last_update_submitted_qc>April 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Virginia Medical School</investigator_affiliation>
    <investigator_full_name>Thomas Kimble</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Contraception</keyword>
  <keyword>Nuvaring</keyword>
  <keyword>Vaginal inflammation</keyword>
  <keyword>Bacterial vaginosis</keyword>
  <keyword>Nugent score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>NuvaRing</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

